ConductScience.org, home

Paper17469105

BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.

Pers JO and 12 others. Arthritis Rheum, 2007. Cited by 171 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Papers, record 17469105. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17469105

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
PubMed
Journal
Arthritis Rheum
PubMed
Year
2007
PubMed
Publication types
Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
171
iCite
Relative citation ratio, by iCite
3.91
iCite
Revised in PubMed
2015-11-19
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pers JOJacques-Olivier
2Devauchelle VValérie
3Daridon CCapucine
4Bendaoud BBoutahar
5Le Berre RRozenn
6Bordron AAnne
7Hutin PPascal
8Renaudineau YYves
9Dueymes MMaryvonne
10Loisel SSéverine
11Berthou CChristian
12Saraux AAlain
13Youinou PPierre

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Antirheumatic AgentsMajor topic
B-Cell Activating FactorMajor topic
B-LymphocytesMajor topic
Sjogren's SyndromeMajor topic
Antibodies, Monoclonal, Murine-Derived
B-Lymphocyte Subsets
Biopsy
Dose-Response Relationship, Drug
Humans
Lymphocyte Depletion
Rituximab
Salivary Glands

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in17469093Will targeting B cells be the answer for Sjögren's syndrome?https://conductscience.org/library/papers/17469093

Source PubMed

Download CSV of comments and corrections

Cited by60

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 171 citations.

PMIDTitleJournalYearIn PapersSource
42342283Emerging treatments for Sjögren's disease: promising drugs on the horizon.RMD Open2026https://conductscience.org/library/papers/42342283PubMed
41912841Evaluation of Effectiveness of Long-Term Therapy with Russian Rituximab Biosimilar (Acellbia) in Sjogren's Disease in Real Clinical Practice.Dokl Biochem Biophys2026https://conductscience.org/library/papers/41912841PubMed
41456033Successful outcome of Rituximab treatment based on lymphocyte immunophenotyping in active Thyroid Eye Disease: a case report.Thyroid Res2025https://conductscience.org/library/papers/41456033PubMed
40646392The Treatment of Primary Biliary Cholangitis: Time for Personalized Medicine.Clin Rev Allergy Immunol2025https://conductscience.org/library/papers/40646392PubMed
39469708Immune and non-immune mediators in the fibrosis pathogenesis of salivary gland in Sjögren's syndrome.Front Immunol2024https://conductscience.org/library/papers/39469708PubMed
39209370Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sjögren's disease.RMD Open2024https://conductscience.org/library/papers/39209370PubMed
39061958Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease.Biomedicines2024https://conductscience.org/library/papers/39061958PubMed
37751119B cell repopulation trajectory after rituximab treatment in autoimmune diseases: a longitudinal observational study.Clin Exp Med2023https://conductscience.org/library/papers/37751119PubMed
37446355Outline of Salivary Gland Pathogenesis of Sjögren's Syndrome and Current Therapeutic Approaches.Int J Mol Sci2023https://conductscience.org/library/papers/37446355PubMed
36477362A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome.JCI Insight2022https://conductscience.org/library/papers/36477362PubMed
36029718Dual B-cell targeting therapy ameliorates autoimmune cholangitis.J Autoimmun2022https://conductscience.org/library/papers/36029718PubMed
34951923New developments in Sjogren's syndrome.Rheumatology (Oxford)2021https://conductscience.org/library/papers/34951923PubMed
34788412Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?Rheumatology (Oxford)2022https://conductscience.org/library/papers/34788412PubMed
34476406Short-term Immunopathological Changes Associated with Pulse Steroids/IVIG/Rituximab Therapy in Late Kidney Allograft Antibody Mediated Rejection.Kidney3602020https://conductscience.org/library/papers/34476406PubMed
34336905Biological Therapy in Primary Sjögren's Syndrome: Effect on Salivary Gland Function and Inflammation.Front Med (Lausanne)2021https://conductscience.org/library/papers/34336905PubMed
32573488Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapses.JCI Insight2020https://conductscience.org/library/papers/32573488PubMed
32547535Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.Front Immunol2020https://conductscience.org/library/papers/32547535PubMed
31508200Recent advances in the search for a targeted immunomodulatory therapy for primary Sjögren's syndrome.F1000Res2019https://conductscience.org/library/papers/31508200PubMed
30472652Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome.Ann Rheum Dis2019https://conductscience.org/library/papers/30472652PubMed
29416129B cells in the pathogenesis of primary Sjögren syndrome.Nat Rev Rheumatol2018https://conductscience.org/library/papers/29416129PubMed

See all 60 cited byDownload CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD19930PubTator's text mininghttps://conductscience.org/library/genes/930NCBI Gene
CD38952PubTator's text mininghttps://conductscience.org/library/genes/952NCBI Gene
CD5921PubTator's text mininghttps://conductscience.org/library/genes/921NCBI Gene
TNFSF13B10673PubTator's text mininghttps://conductscience.org/library/genes/10673NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17469105

GET https://conductscience.org/api/papers/v1/17469105/cited_by?page=2